Literature DB >> 18451724

Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions.

Daniela Pohl1.   

Abstract

PURPOSE OF REVIEW: Pediatric inflammatory demyelinating central nervous system diseases comprise monofocal and potentially monophasic disorders like optic neuritis and transverse myelitis, the multifocal, self-limiting disorder of acute disseminated encephalomyelitis, and multifocal chronic diseases like relapsing neuromyelitis optica and multiple sclerosis. This review discusses characteristics of these disorders with focus on epidemiology and treatment of acute disseminated encephalomyelitis, neuromyelitis optica and multiple sclerosis. RECENT
FINDINGS: An international consensus group very recently defined diagnostic criteria for pediatric multiple sclerosis and acute disseminated encephalomyelitis. Immunological studies on pediatric inflammatory demyelinating disorders revealed possible disease-related humoral and T-cellular pathomechanisms. The recently identified biomarker for neuromyelitis optica, aquaporin-4-autoantibody, was detected in children with relapsing neuromyelitis optica with a similar frequency as in adult neuromyelitis optica patients. Clinically relevant, there is growing evidence that disease-modifying treatments are well tolerated and effective in the pediatric age group also.
SUMMARY: Recent studies on pediatric inflammatory demyelinating central nervous system diseases have contributed to current awareness that these disorders are not restricted to the adult age group, and that some of them carry an unfavorable long-term prognosis. Growing knowledge will hopefully enable more timely diagnoses and more specifically tailored therapies in the near future, with the goal of improving outcomes in this young patient group.

Entities:  

Mesh:

Year:  2008        PMID: 18451724     DOI: 10.1097/WCO.0b013e3282fd172b

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  8 in total

1.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

2.  Treatment of acute disseminated encephalomyelitis.

Authors:  Daniela Pohl; Silvia Tenembaum
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.972

3.  Rare brain biopsy findings in a first ADEM-like event of pediatric MS: histopathologic, neuroradiologic and clinical features.

Authors:  Franziska Hoche; Sabine Pfeifenbring; Stefan Vlaho; Mayyada Qirshi; Marius Theis; Wilfried Schneider; Luciana Porto; Klaus Müller; Matthias Kieslich
Journal:  J Neural Transm (Vienna)       Date:  2011-03-10       Impact factor: 3.575

Review 4.  Management of multiple sclerosis in adolescents - current treatment options and related adherence issues.

Authors:  Jean K Mah; Jennifer E Thannhauser
Journal:  Adolesc Health Med Ther       Date:  2010-06-17

5.  Current options for the treatment of optic neuritis.

Authors:  John H Pula; Christopher J Macdonald
Journal:  Clin Ophthalmol       Date:  2012-07-31

6.  Diagnostic challenges in a child with familial hemophagocytic lymphohistiocytosis type 3 (FHLH3) presenting with fulminant neurological disease.

Authors:  James D Weisfeld-Adams; Yitzchak Frank; Vinod Havalad; Joanne M Hojsak; Roberto Posada; Shipra M Kaicker; Birte Wistinghausen
Journal:  Childs Nerv Syst       Date:  2008-11-21       Impact factor: 1.532

7.  Acute measles encephalitis in partially vaccinated adults.

Authors:  Annette Fox; Than Manh Hung; Heiman Wertheim; Le Nguyen Minh Hoa; Angela Vincent; Bethan Lang; Patrick Waters; Nguyen Hong Ha; Nguyen Vu Trung; Jeremy Farrar; Nguyen Van Kinh; Peter Horby
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

8.  Blinded continuous monitoring in clinical trials with recurrent event endpoints.

Authors:  Tim Friede; Dieter A Häring; Heinz Schmidli
Journal:  Pharm Stat       Date:  2018-10-21       Impact factor: 1.894

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.